|
Alniche Lifesciences to expand into cardio-diabetic, gastro-hepatic areas
|
|
Yash Ved, Mumbai
September 25 , 2021
|
|
|
Alniche Lifesciences is planning to expand into new therapy areas such as cardio-diabetic and gastro-hepatic. This includes the introduction of value-added products to take care of vital organs of circulatory and digestive systems that are severely affected due to Covid pandemic.
The company added that it intends to broaden its reach through exports, since Indian pharmaceutical products possess a high reputation in other countries, putting India among the top five pharmaceutical exporters in the world.
“Apart from exports, the institutional supplies have enormous potential, as the government is the largest consumer under various health schemes. We will be successfully competing in this business by supplying quality products from our manufacturing unit – Effikasia Lifesciences. We remain open to the companies that can partner with us for R&D and Global expansions,” stated Girish Arora, founder & MD of Alniche Lifesciences.
The company’s vision is to bring medicines and market across a wide range of therapies, as well as to become the chosen partner of global lifesciences enterprises and mission is to offer the best quality medicines to the maximum number of people for which Alniche is maximizing the business potential of both domestic and international partners.
Girish added that the company's plan is to combine marketing strategy with a niche portfolio to approach the targeted doctors. This includes programmes such as CMEs, symposia, teleconsultations, disease information and management, advocacy development, and the most recent therapeutic regimen - book release, practice support, and decision enhancement tools, to name a few.
With a strong product portfolio, both domestic manufactured and licensed from global pharma, Alniche fulfills the unmet needs of patients in the areas of nephrology, critical Care, gastroenterology, dermatology and neuropsychiatry.
Alniche has 700+ employees with 1500+ distribution points both for prescription and OTX brands, covering 70,000 doctors and 30,000 hospitals. Alniche has emerged as a fierce competitor in nephrology and critical care segment and is continuing the success story in newly expanded therapy segments.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|